Quince Therapeutics, Inc. Proceeds from Notes Payable
Quince Therapeutics, Inc. (QNCX) reported Proceeds from Notes Payable of $250.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2021-03-01
- Quince Therapeutics, Inc. proceeds from notes payable for the quarter ending 2018-12-31 was $0.00.
- Quince Therapeutics, Inc. proceeds from notes payable for the quarter ending 2018-09-30 was $0.00.
- Quince Therapeutics, Inc. proceeds from notes payable for the quarter ending 2018-06-30 was $0.00.
- Quince Therapeutics, Inc. proceeds from notes payable for the quarter ending 2018-03-31 was $250.00K.
- Quince Therapeutics, Inc. proceeds from notes payable for fiscal 2018 was $250.00K.
| Period end | Proceeds from Notes Payable 1 month | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $250.00K 10-K · filed 2021-03-01 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $250.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $250.00K 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | $250.00K 10-Q · filed 2019-06-12 | ||||
| 2018-01-31 | $250.00K 10-K · filed 2021-03-01 | ||||
| 2017-06-30 | $150.00K 10-K · filed 2021-03-01 | ||||
| 2017-02-28 | $7.60M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |